vs

Side-by-side financial comparison of SBA Communications (SBAC) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

DENTSPLY SIRONA Inc. is the larger business by last-quarter revenue ($961.0M vs $703.4M, roughly 1.4× SBA Communications). SBA Communications runs the higher net margin — 26.3% vs -15.2%, a 41.5% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs -1.6%). Over the past eight quarters, SBA Communications's revenue compounded faster (3.2% CAGR vs 0.4%).

SBA Communications Corporation is a real estate investment trust which owns and operates wireless infrastructure in the United States, Canada, Central America, South America, and South Africa. It was founded in 1989 as Steven Bernstein and Associates by Steven Bernstein.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

SBAC vs XRAY — Head-to-Head

Bigger by revenue
XRAY
XRAY
1.4× larger
XRAY
$961.0M
$703.4M
SBAC
Growing faster (revenue YoY)
XRAY
XRAY
+7.7% gap
XRAY
6.2%
-1.6%
SBAC
Higher net margin
SBAC
SBAC
41.5% more per $
SBAC
26.3%
-15.2%
XRAY
Faster 2-yr revenue CAGR
SBAC
SBAC
Annualised
SBAC
3.2%
0.4%
XRAY

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
SBAC
SBAC
XRAY
XRAY
Revenue
$703.4M
$961.0M
Net Profit
$184.9M
$-146.0M
Gross Margin
46.1%
Operating Margin
48.7%
-14.5%
Net Margin
26.3%
-15.2%
Revenue YoY
-1.6%
6.2%
Net Profit YoY
-15.1%
66.0%
EPS (diluted)
$1.74
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SBAC
SBAC
XRAY
XRAY
Q1 26
$703.4M
Q4 25
$719.6M
$961.0M
Q3 25
$732.3M
$904.0M
Q2 25
$699.0M
$936.0M
Q1 25
$664.2M
$879.0M
Q4 24
$693.7M
$905.0M
Q3 24
$667.6M
$951.0M
Q2 24
$660.5M
$984.0M
Net Profit
SBAC
SBAC
XRAY
XRAY
Q1 26
$184.9M
Q4 25
$370.4M
$-146.0M
Q3 25
$236.8M
$-427.0M
Q2 25
$225.8M
$-45.0M
Q1 25
$220.7M
$20.0M
Q4 24
$178.8M
$-430.0M
Q3 24
$258.5M
$-494.0M
Q2 24
$162.8M
$-4.0M
Gross Margin
SBAC
SBAC
XRAY
XRAY
Q1 26
Q4 25
75.6%
46.1%
Q3 25
74.1%
48.8%
Q2 25
75.4%
52.4%
Q1 25
76.9%
53.0%
Q4 24
78.1%
49.3%
Q3 24
77.5%
52.1%
Q2 24
78.6%
51.9%
Operating Margin
SBAC
SBAC
XRAY
XRAY
Q1 26
48.7%
Q4 25
41.5%
-14.5%
Q3 25
51.1%
-24.1%
Q2 25
47.9%
-13.7%
Q1 25
50.4%
7.2%
Q4 24
55.1%
-56.2%
Q3 24
56.3%
-48.6%
Q2 24
53.7%
5.1%
Net Margin
SBAC
SBAC
XRAY
XRAY
Q1 26
26.3%
Q4 25
51.5%
-15.2%
Q3 25
32.3%
-47.2%
Q2 25
32.3%
-4.8%
Q1 25
33.2%
2.3%
Q4 24
25.8%
-47.5%
Q3 24
38.7%
-51.9%
Q2 24
24.7%
-0.4%
EPS (diluted)
SBAC
SBAC
XRAY
XRAY
Q1 26
$1.74
Q4 25
$3.47
$-0.74
Q3 25
$2.20
$-2.14
Q2 25
$2.09
$-0.22
Q1 25
$2.04
$0.10
Q4 24
$1.61
$-2.09
Q3 24
$2.40
$-2.46
Q2 24
$1.51
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SBAC
SBAC
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$269.1M
$326.0M
Total DebtLower is stronger
$2.7B
$2.3B
Stockholders' EquityBook value
$1.3B
Total Assets
$11.7B
$5.4B
Debt / EquityLower = less leverage
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SBAC
SBAC
XRAY
XRAY
Q1 26
$269.1M
Q4 25
$271.2M
$326.0M
Q3 25
$431.1M
$363.0M
Q2 25
$276.8M
$359.0M
Q1 25
$702.2M
$398.0M
Q4 24
$444.4M
$272.0M
Q3 24
$202.6M
$296.0M
Q2 24
$250.9M
$279.0M
Total Debt
SBAC
SBAC
XRAY
XRAY
Q1 26
$2.7B
Q4 25
$12.9B
$2.3B
Q3 25
$12.7B
Q2 25
$12.5B
Q1 25
$12.4B
Q4 24
$13.6B
$1.7B
Q3 24
$12.3B
Q2 24
$12.3B
Stockholders' Equity
SBAC
SBAC
XRAY
XRAY
Q1 26
Q4 25
$-4.9B
$1.3B
Q3 25
$-4.9B
$1.5B
Q2 25
$-4.9B
$2.0B
Q1 25
$-5.0B
$2.0B
Q4 24
$-5.1B
$1.9B
Q3 24
$-5.2B
$2.5B
Q2 24
$-5.3B
$3.1B
Total Assets
SBAC
SBAC
XRAY
XRAY
Q1 26
$11.7B
Q4 25
$11.6B
$5.4B
Q3 25
$11.3B
$5.7B
Q2 25
$10.8B
$6.1B
Q1 25
$10.4B
$6.0B
Q4 24
$11.4B
$5.8B
Q3 24
$10.2B
$6.6B
Q2 24
$9.8B
$6.9B
Debt / Equity
SBAC
SBAC
XRAY
XRAY
Q1 26
Q4 25
1.70×
Q3 25
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SBAC
SBAC
XRAY
XRAY
Operating Cash FlowLast quarter
$255.1M
$101.0M
Free Cash FlowOCF − Capex
$60.0M
FCF MarginFCF / Revenue
6.2%
Capex IntensityCapex / Revenue
9.5%
4.3%
Cash ConversionOCF / Net Profit
1.38×
TTM Free Cash FlowTrailing 4 quarters
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SBAC
SBAC
XRAY
XRAY
Q1 26
$255.1M
Q4 25
$1.3B
$101.0M
Q3 25
$318.0M
$79.0M
Q2 25
$368.1M
$48.0M
Q1 25
$301.2M
$7.0M
Q4 24
$1.3B
$87.0M
Q3 24
$304.7M
$141.0M
Q2 24
$425.6M
$208.0M
Free Cash Flow
SBAC
SBAC
XRAY
XRAY
Q1 26
Q4 25
$833.3M
$60.0M
Q3 25
$258.0M
$40.0M
Q2 25
$312.2M
$16.0M
Q1 25
$255.0M
$-12.0M
Q4 24
$1.2B
$36.0M
Q3 24
$239.9M
$98.0M
Q2 24
$375.6M
$156.0M
FCF Margin
SBAC
SBAC
XRAY
XRAY
Q1 26
Q4 25
115.8%
6.2%
Q3 25
35.2%
4.4%
Q2 25
44.7%
1.7%
Q1 25
38.4%
-1.4%
Q4 24
179.9%
4.0%
Q3 24
35.9%
10.3%
Q2 24
56.9%
15.9%
Capex Intensity
SBAC
SBAC
XRAY
XRAY
Q1 26
9.5%
Q4 25
63.7%
4.3%
Q3 25
8.2%
4.3%
Q2 25
8.0%
3.4%
Q1 25
7.0%
2.2%
Q4 24
12.6%
5.6%
Q3 24
9.7%
4.5%
Q2 24
7.6%
5.3%
Cash Conversion
SBAC
SBAC
XRAY
XRAY
Q1 26
1.38×
Q4 25
3.49×
Q3 25
1.34×
Q2 25
1.63×
Q1 25
1.36×
0.35×
Q4 24
7.47×
Q3 24
1.18×
Q2 24
2.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SBAC
SBAC

Site leasing$656.1M93%
Site development$47.3M7%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons